Heart and Vascular Diseases

Dietary supplements can be valuable in supporting the management of cardiovascular conditions.
Diet and exercise remain the most important lifestyle changes to make; supplements can provide valuable support.

The following nutrients can be used (daily doses):

-Vitamin K2, 0.180–0.360 mg
-Vitamin D, 3000–5000 IU
-Magnesium, 300–500 mg
-Green tea extract, 300–500 mg EGCG
-curcumin, 500–1000 mg
-resveratrol, 100–200 mg
-omega-3, 1000–2000 mg EPA+DHA
-vitamin C, 1000–2000 mg
-L-Taurine, 500–1500 mg
-Red Yeast Rice with 10 mg monacolin K. This can be an alternative to the classic statins that are prescribed.
The 10 mg dosage (therapeutic dosage) is available only by prescription at the pharmacy.

The low doses available as dietary supplements are not very effective.
Most of these risk factors are entirely within your control and can be prevented by following a healthy diet and sufficient physical activity exercise.

What preventive measures can you take?

Chelation therapy

EDTA chelation therapy is a very safe detoxification therapy in which a synthetic amino acid (EDTA, or ethylenediaminetetraacetate) is administered via an IV drip. This amino acid has the property of readily binding to metals and minerals. This bond is called a chelate. Heavy metals in particular (such as lead, cadmium, and mercury) have a strong affinity for EDTA and form strong bonds with it.

In the 1940s and 1950s, doctors treating heart patients with lead poisoning discovered that their patients experienced a significant reduction in heart symptoms.

I have been using chelation therapy in my practice for over twenty years. It is a therapy with no side effects. I have administered thousands of infusions and have found that the therapy is particularly effective for blockages in the blood vessels of the legs and around the heart.

Over the past twenty years, chelation therapy has been studied by many scientists, who have documented its mechanisms of action and beneficial effects. In 1993, a study was published showing that patients who had suffered a heart attack and subsequently underwent chelation therapy had a significantly reduced risk of another heart attack. Seventy percent were symptom-free after three years, and their quality of life had greatly improved: they could climb stairs more easily, were less prone to shortness of breath, experienced increased blood flow to their lower limbs, had less leg pain, and so on.

A 2014 study (double-blind, placebo-controlled) has shown that EDTA chelation therapy is indeed effective.
Diabetes patients in particular benefit from it. These patients are highly susceptible to cardiovascular diseases as a result
of their condition. Among diabetics, there was a 43 percent reduction in mortality, post-operative recurrence, and readmission to the hospital for heart problems. Other patients experienced an 18 percent reduction in the recurrence of cardiovascular problems.

Chelation therapy can also be used preventively to prevent atherosclerosis. It can be administered after bypass surgery to prevent further heart attacks. In many cases, chelation therapy is a safe alternative to heart surgery, and it can often prevent the need for leg surgery due to blocked blood vessels. In many cases, chelation therapy can help avoid the need for an amputation or heart surgery.

In my view, chelation therapy is a highly valuable complementary therapy, as part of a comprehensive treatment plan in which a healthy diet, exercise, stress reduction, and dietary supplements are also of fundamental importance. The therapy has also proven its value as a complement to conventional medications.

Chelation therapy affects two processes and therefore works in two ways:

  1. EDTA neutralizes free radicals. When free radicals are allowed to run rampant under certain conditions (smoking, stress, an unhealthy diet, air pollution, excessive alcohol consumption, certain medications), they damage cells, leading to accelerated aging, cancer, and atherosclerosis. The production and activity of these free radicals can be influenced by heavy metals in the bloodstream. Chelation therapy ensures that these heavy metals are eliminated.
  2. EDTA binds not only heavy metals but also calcium. This has a positive effect on the calcium-to-magnesium ratio, which in turn has a beneficial impact on the atherosclerosis process.

In practice, the active ingredient EDTA is administered via an IV drip along with a cocktail of vitamins, minerals, and amino acids. The treatment is administered once or twice a week and must be repeated 20 to 50 times, depending on the indication.

Publications:

1.

Chelation therapy for the treatment of atherosclerosis, particularly in patients with diabetes: is it time to reconsider?

Lamas GA, Ergui I.
Expert Review of Cardiovascular Therapy. August 2016;14(8):927-38. doi: 10.1080/14779072.2016.1180977. Published online May 5, 2016.
2.

The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT).

Ujueta F, Arenas IA, Escolar E, Diaz D, Boineau R, Mark DB, Golden P, Lindblad L, Kim H, Lee KL, Lamas GA.
J Diabetes Complications. July 2019;33(7):490-494. doi: 10.1016/j.jdiacomp.2019.04.005. Published online April 2019
3.

EDTA chelation therapy alone and in combination with high-dose oral multivitamins and minerals for coronary artery disease: The factorial group results of the Trial to Assess Chelation Therapy.

Lamas GA, Boineau R, Goertz C, Mark DB, Rosenberg Y, Stylianou M, Rozema T, Nahin RL, Terry Chappell L, Lindblad L, Lewis EF, Drisko J, Lee KL.
Am Heart J. July 2014;168(1):37-44.e5. doi: 10.1016/j.ahj.2014.02.012. Published online April 2, 2014.
4.

Chelation therapy following the trial to evaluate chelation therapy: results of a unique trial.

Avila MD, Escolar E, Lamas GA.
Curr Opin Cardiol. September 2014;29(5):481-8. doi: 10.1097/HCO.0000000000000096.
5.

Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy.

Lamas GA, Navas-Acien A, Mark DB, Lee KL.
J Am Coll Cardiol. May 24, 2016;67(20):2411-2418. doi: 10.1016/j.jacc.2016.02.066.